These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
576 related articles for article (PubMed ID: 22044430)
1. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice. Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430 [TBL] [Abstract][Full Text] [Related]
2. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. Reipert BM; van Helden PM; Schwarz HP; Hausl C Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196 [TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice. Qadura M; Waters B; Burnett E; Chegeni R; Hough C; Othman M; Lillicrap D Haemophilia; 2011 Mar; 17(2):288-95. PubMed ID: 21091850 [TBL] [Abstract][Full Text] [Related]
4. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance. Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297 [TBL] [Abstract][Full Text] [Related]
6. Immune tolerance induction in patients with hemophilia A. Astermark J Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905 [TBL] [Abstract][Full Text] [Related]
7. Factor VIII-specific B cell responses in haemophilia A patients with inhibitors. van Helden PM; Van Haren SD; Fijnvandraat K; van den Berg HM; Voorberg J Haemophilia; 2010 May; 16(102):35-43. PubMed ID: 20536984 [TBL] [Abstract][Full Text] [Related]
8. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate. Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM; Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086 [TBL] [Abstract][Full Text] [Related]
9. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units. Ter Avest PC; Fischer K; Gouw SC; Van Dijk K; Mauser-Bunschoten EP Haemophilia; 2010 May; 16(102):71-9. PubMed ID: 20536988 [TBL] [Abstract][Full Text] [Related]
10. Novel therapies for immune tolerance in haemophilia A. Collins PW Haemophilia; 2006 Dec; 12 Suppl 6():94-100; discussion 100-1. PubMed ID: 17123401 [TBL] [Abstract][Full Text] [Related]
11. Long-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII. Liu CL; Ye P; Lin J; Djukovic D; Miao CH J Thromb Haemost; 2014 Jun; 12(6):921-31. PubMed ID: 24684505 [TBL] [Abstract][Full Text] [Related]
12. The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture? Ettingshausen CE; Kreuz W Haemophilia; 2013 Jan; 19 Suppl 1():12-7. PubMed ID: 23278995 [TBL] [Abstract][Full Text] [Related]
14. Central venous access devices for paediatric patients with haemophilia: a single-institution experience. Titapiwatanakun R; Moir C; Pruthi RK; Stavlo PL; Schmidt KA; Rodriguez V Haemophilia; 2009 Jan; 15(1):168-74. PubMed ID: 19149849 [TBL] [Abstract][Full Text] [Related]
15. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients. Hu G; Guo D; Key NS; Conti-Fine BM Thromb Haemost; 2007 May; 97(5):788-94. PubMed ID: 17479189 [TBL] [Abstract][Full Text] [Related]
16. Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A. Madoiwa S; Yamauchi T; Hakamata Y; Kobayashi E; Arai M; Sugo T; Mimuro J; Sakata Y J Thromb Haemost; 2004 May; 2(5):754-62. PubMed ID: 15099282 [TBL] [Abstract][Full Text] [Related]
18. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin. Biswas M; Rogers GL; Sherman A; Byrne BJ; Markusic DM; Jiang H; Herzog RW Thromb Haemost; 2017 Jan; 117(1):33-43. PubMed ID: 27683758 [TBL] [Abstract][Full Text] [Related]
19. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A. Valentino LA; Recht M; Dipaola J; Shapiro AD; Pipe SW; Ewing N; Urgo J; Bullock T; Simmons M; Deguzman C Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383 [TBL] [Abstract][Full Text] [Related]
20. Induction of tolerance to factor VIII by transient co-administration with rapamycin. Moghimi B; Sack BK; Nayak S; Markusic DM; Mah CS; Herzog RW J Thromb Haemost; 2011 Aug; 9(8):1524-33. PubMed ID: 21585650 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]